What does a nodule or shadow found in the lungs on a CT report mean?
A nodule found in the lung (pulmonary nodule) is a well-circumscribed, round or oval area on a CT scan, typically measuring less than 3 cm. A shadow (opacity) may denote a more diffuse, extensive lesion. Nodules are extremely common: in a screening study, they were detectable in up to 51% of smokers (pmid:16244247). Most such lesions are benign; they may represent scar tissue (granuloma) resulting from prior inflammation or infection (e.g., tuberculosis, fungal infection), a benign tumour (e.g., hamartoma), or part of an autoimmune disease (e.g., a rheumatoid nodule). Malignant nodules most frequently arise from primary lung cancer (adenocarcinoma, squamous cell carcinoma, small cell lung cancer) or from metastases originating from other organs.
The radiologist assesses multiple features on the CT scan that help estimate the risk of malignancy. These include nodule size (nodules larger than 10 mm are more likely to be malignant, whereas multiple, tiny nodules are more suggestive of benignity – pmid:42066465), margin irregularity (spiculation, lobulation – these are independent risk factors, pmid:42577057), density (purely solid, ground-glass opacity, or mixed/part-solid), and growth rate. It is an especially concerning sign if the nodule is newly identified or growing compared to a prior examination; according to a large study, growing nodules carry a nearly 20-fold risk, and newly emergent nodules a 4-fold risk, of malignancy (pmid:41850482). The persistence of ground-glass opacity can often indicate early-stage lung adenocarcinoma, while a purely solid, rapidly growing nodule may suggest a more aggressive tumour.
Management is determined by the nodule's characteristics and the patient's individual risk factors (age, smoking history, family history). Based on the Fleischner Society guidelines (pmid:16244247) and the Lung-RADS classification (pmid:41667372), regular follow-up CT surveillance (e.g., at 3, 6, or 12 months) is sufficient for most small nodules. For larger, suspicious nodules, further imaging (PET/CT) or histological sampling (CT-guided biopsy, bronchoscopy) is required. It is important to emphasise that the overwhelming majority of nodules discovered on CT are not cancer, especially those smaller than 6 mm. Nevertheless, a pulmonologist or oncologist should always be consulted for accurate interpretation of the findings and a personalised follow-up plan. Modern artificial intelligence tools increasingly assist radiologists in detecting and characterising nodules, but a biopsy is often required for a definitive diagnosis.
A variety of benign and malignant processes may underlie nodules and shadows found in the lungs. Benign causes include residual scars following prior infections (e.g., tuberculosis, fungal infections, bacterial abscesses), termed granulomas; benign tumours such as hamartoma, fibroma, or the rare sclerosing pneumocytoma; as well as autoimmune conditions such as rheumatoid arthritis, which can cause pulmonary nodules. Chronic inflammatory changes are also common in smokers. In the case of malignant nodules, these represent primary lung cancer (adenocarcinoma, squamous cell carcinoma, small cell carcinoma) or metastases from another organ (e.g., breast, colon, kidney). The characteristics of the nodules—such as size, growth rate, and patient history—help in differentiation.
Detailed analysis of the CT scan is crucial in evaluating the nature of the nodule. Radiologists assess the following features: - Size: nodules larger than 10 mm have a higher probability of malignancy (pmid:42066465). - Shape and margins: irregular, spiculated, or lobulated margins suggest malignancy (pmid:42577057). - Density: ground-glass opacity (GGO) and mixed (part-solid, part-GGO) nodules often indicate early-stage adenocarcinoma; purely solid nodules may be more aggressive. - Growth: new or growing nodules represent an elevated risk (pmid:41850482). - Location: nodules located in the upper lobes are more likely to be malignant. The Fleischner Society 2005 guidelines (pmid:16244247) provide recommendations for the timing of follow-up CT scans based on size and the patient's risk category. Modern artificial intelligence systems detect and classify nodules with increasing accuracy, but they do not replace clinical decision-making.
If a nodule or shadow is identified on a CT report, the next step depends on the nodule's risk stratification. For low-risk, small nodules (e.g., under 6 mm), a follow-up CT scan at 6–12 months is generally sufficient, as recommended by the Fleischner guidelines. For intermediate- or high-risk nodules (e.g., larger than 8–10 mm, growing, or in a high-risk patient), further imaging (FDG-PET/CT) or histological sampling may become necessary. Biopsy can be performed via CT-guided percutaneous puncture, bronchoscopy, or even navigational techniques. The Lung-RADS system (pmid:41667372) helps standardise the classification of nodules detected during screening examinations. It is important that the patient always consults a specialist in pulmonology or oncology, who will determine the necessary course of action based on the overall clinical picture. The majority of nodules are benign, so panic is unnecessary; however, regular follow-up and adherence to specialist instructions are essential.
References
- Construction and validation of a prediction model for malignant pulmonary nodules based on imaging, demographic, and laboratory features. PMID 42577057
- Use of a single-scan Lung-RADS for pulmonary nodule assessment in resource-limited clinical settings. PMID 41667372
- Association of New and Growing Nodules With Malignancy in Follow-Up Screening for Lung Cancer: A Cohort Study. PMID 41850482
- Characteristics of lung nodules detected by low-dose CT scan: Results from the French lung cancer screening study DEP KP-80. PMID 42066465
- Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement from the Fleischner Society PMID 16244247
- PMID 16244247